Oppenheimer analyst Leland Gershell reiterated a Perform rating on Teva Pharma (NYSE: TEVA).The analyst comments "4Q23 top- and bottom-line beats ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE